Details

Autor(en) / Beteiligte

• Do Minh, Duc
• Chapiro, Julius
• Gorodetski, Boris
• Huang, Qiang
• Liu, Cuihong
• Smolka, Susanne
• Savic, Lynn Jeanette
• Wainstejn, David
• Lin, MingDe
• Schlachter, Todd
• Gebauer, Bernhard
• Geschwind, Jean-François

Titel

Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model

Ist Teil von

• European radiology, 2017-12, Vol.27 (12), p.4995-5005

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2017

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• Objectives To compare efficacy, survival outcome and prognostic factors of conventional transarterial chemoembolisation (cTACE), drug-eluting beads TACE (DEB-TACE) and yttrium-90 radioembolisation (Y90) for the treatment of liver metastases from gastroenteropancreatic (GEP) neuroendocrine tumours (NELM). Methods This retrospective analysis included 192 patients (58.6 years mean age, 56% men) with NELM treated with cTACE ( N  = 122), DEB-TACE ( N  = 26) or Y90 ( N  = 44) between 2000 and 2014. Radiologic response to therapy was assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) and World Health Organization (WHO) criteria using periprocedural MR imaging. Survival analysis included propensity score analysis (PSA), median overall survival (MOS), hepatic progression-free survival, Kaplan–Meier using log-rank test and the uni- and multivariate Cox proportional hazards model (MVA). Results MOS of the entire study population was 28.8 months. As for cTACE, DEB-TACE and Y90, MOS was 33.8 months, 21.7 months and 23.6 months, respectively. According to the MVA, cTACE demonstrated a significantly longer MOS as compared to DEB-TACE ( p  <.01) or Y90 ( p  = .02). The 5-year survival rate after initial cTACE, DEB-TACE and Y90 was 28.2%, 10.3% and 18.5%, respectively. Conclusions Upon PSA, our study suggests significant survival benefits for patients treated with cTACE as compared to DEB-TACE and Y90. This data supports the therapeutic decision for cTACE as the primary intra-arterial therapy option in patients with unresectable NELM until proven otherwise. Key Points • cTACE achieved a significantly longer overall survival in patients with unresectable NELM. • Patients treated with cTACE showed a prolonged hepatic progression-free survival. • cTACE, DEB-TACE and Y90 radioembolisation demonstrated comparable safety and toxicity profiles. • Age >70 years, extrahepatic metastases and tumour burden >50% were identified as negative predictors. • Propensity score analysis suggests the superiority of cTACE over DEB-TACE and Y90.